Mounjaro®
Starting from £179.99/mo
Start journey Learn moreConstipation is one of the most common side effects of Mounjaro (tirzepatide), reported by a meaningful proportion of people in the SURMOUNT trials. The best laxative approach while taking Mounjaro starts with osmotic agents — particularly macrogol (polyethylene glycol) — which soften stools gently without stimulating gut contractions that can worsen existing nausea. This is a clinical decision, not a one-size-fits-all answer, and it sits squarely in the territory your prescriber should know about. Mounjaro slows gastric emptying significantly as part of how it works, so the gut transit changes you feel are a direct pharmacological effect, not coincidence. Getting the right support in place early matters, especially if you're starting a new dose and the side-effect burden peaks in the first week or two.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Most constipation guidance assumes a normally moving gut. Mounjaro changes that baseline. As a dual GIP and GLP-1 receptor agonist, it slows the rate at which food moves through the stomach and small intestine, that is part of what produces fullness and reduces appetite. The knock-on for the large bowel is slower transit, harder stools and, for many people, constipation that feels different to anything they've experienced before.
The timing matters too. Symptoms tend to cluster in the first one to two weeks after a dose is taken, or after a dose increase. If you're titrating up through the 2.5mg starter pen and nausea is already a feature, adding a stimulant laxative that causes cramping on top of that is rarely a comfortable experience. The NHS tirzepatide information page lists constipation among the common side effects and advises speaking to a pharmacist or doctor if it is troublesome. That is exactly the right instinct, getting the choice right matters here. Some people find that what feels like constipation in the first fortnight resolves as the body adjusts; others need ongoing support throughout treatment.
Keeping a simple note of when it started and how it relates to your injection day gives a prescriber genuinely useful information. If you use a consistent injection day, that pattern is easier to spot.
There are four main laxative classes available in UK pharmacies, and they are not interchangeable for someone on Mounjaro.
Osmotic laxatives (macrogol (Movicol, Laxido) and lactulose) draw water into the bowel, softening stool without triggering muscle contractions. For most people on Mounjaro, macrogol is the first choice the NHS and pharmacists reach for: it is well tolerated, gentle and does not add to gut spasm. Lactulose is an alternative but can cause bloating and flatulence, which may sit badly alongside existing GI side effects.
Bulk-forming laxatives (ispaghula husk (Fybogel)) add fibre volume to the stool. They work well alongside good hydration, but require adequate fluid intake to avoid making things worse. If you are already struggling to drink enough because nausea has reduced your appetite and thirst, bulk-forming agents need careful use.
Stimulant laxatives (senna, bisacodyl) trigger bowel muscle contractions. They are effective for short-term use but can cause cramping. On Mounjaro, where nausea is already a possible companion, cramping from a stimulant laxative is an added burden. Most pharmacists would steer you toward an osmotic option first and keep stimulants as a backup.
Stool softeners (docusate sodium) have a limited evidence base compared to osmotic agents and are rarely the first recommendation in UK clinical practice.
Reading about which foods to prioritise on Mounjaro is worth doing alongside any laxative decision, fibre from food sources (oats, vegetables, legumes) and consistent hydration are the foundation; a laxative is a supplement to that, not a replacement.
The single most underestimated factor is fluid intake. Mounjaro's appetite suppression means many people eat and drink less overall. Less fluid, less dietary fibre, less movement (all of which are natural consequences of appetite reduction) compound the gut-slowing effect of the medicine itself. Before reaching for any laxative, a genuine attempt at 1.5–2 litres of water across the day and a deliberate increase in vegetables and wholegrains is the right first step. It sounds obvious. Most people find they were running noticeably low on both.
One practical timing note: if constipation peaks mid-week after a Monday injection, that pattern can make the working week uncomfortable. Some people find adjusting injection timing helps with scheduling, something worth raising at your next clinical review rather than working around quietly.
If symptoms persist beyond a couple of weeks on your chosen laxative, worsen at any point, or include pain, bleeding or vomiting, these are signals to speak to a doctor promptly rather than continue experimenting. Severe abdominal pain that radiates to the back is something to take seriously without delay, the MHRA's Yellow Card scheme exists for people to report side effects they believe are connected to a medicine, and your prescriber should be in the loop regardless.
For a broader look at how Mounjaro is prescribed and monitored in the UK, the Mounjaro overview sets out the full clinical picture, including dose escalation and what to expect at each stage.
A short-term constipation blip that resolves with macrogol and better hydration does not necessarily need a clinical review. Ongoing constipation that is affecting your quality of life, or that you cannot get on top of with over-the-counter options, absolutely does. Your Mounjaro prescriber needs to know if a side effect is persistent, partly because it may influence the pace of dose titration, and partly because it rules out anything that warrants attention in its own right.
If you are considering Mounjaro and want to understand whether it is appropriate for you, or if you are already on treatment and have questions about managing side effects, speaking with a prescriber is the right next step. You can read about what our clinical team looks at during a review on the clinical team page.
People who are weighing up Mounjaro against other approaches may also find the alternatives to Mounjaro page useful context, given that different medicines carry different GI side-effect profiles. And if pricing is a factor in your thinking, a summary of recent UK list-price changes explains the current landscape plainly.
For most people on Mounjaro, constipation is manageable with the right approach. The key is choosing the correct laxative type, pairing it with hydration and dietary adjustments, and looping in your prescriber if things are not improving. If you want guidance on where to get Mounjaro safely in the UK, that is also worth reviewing before you start or switch provider. If you would like that clinical support, starting a free consultation is the first step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.